首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions
【24h】

Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions

机译:腿部紫杉醇洗脱气球的快速随机试验的短期结果,具有超级螺旋腹腹板,仅用于治疗中间和长浅表股动脉病变

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To report a randomized trial comparing the Legflow paclitaxel-eluting balloon (PEB) + Supera stenting to Supera stenting alone in patients with intermediate to long superficial femoral artery (SFA) lesions. Methods: The multicenter RAPID trial (controlled-trials.com; identifier ISRCTN47846578) randomized (1:1) 160 patients (mean age 67 years; 102 men) with Rutherford category 2-6 ischemia to treatment with Legflow PEB + Supera stent or Supera stent alone in intermediate to long SFA lesions (mean lesion length 15.8 +/- 7.4 vs 15.8 +/- 7.6 cm, respectively). The efficacy outcome was primary patency, defined as freedom from restenosis on duplex ultrasound or angiography. Results: Baseline characteristics including the percentage of occlusions were similar between groups. In the intention-to-treat analysis, the estimated primary patency at 1 year was 68.3% (95% CI 56.7% to 79.9%) in the PEB + Supera group vs 62.0% (95% CI 49.1% to 74.9%) in the Supera group (p = 0.900). Per-protocol analysis showed a 12-month primary patency estimate of 74.7% (95% CI 63.1% to 86.3%) in the PEB + Supera group vs 62.0% (95% CI 49.1% to 74.9%) in the control group (p = 0.273). Secondary patency estimates at 12 months (per-protocol analysis) were 89.0% (95% CI 80.6% to 97.4%) vs 98.0% (95% CI 94.1% to 100%; p = 0.484); the estimates for freedom from clinically driven target lesion revascularization (CD-TLR) were 83.0% (95% CI 72.8% to 93.2%) and 77.8% (95% CI 66.6% to 89.0%; p = 0.277), respectively. Conclusion: The short-term results from the multicenter RAPID randomized controlled trial indicate that the Legflow PEB is safe and feasible for the treatment of intermediate to long SFA lesions. In this trial, at least 70% of the patients suffered an occlusion. The PEB group had higher rates of primary patency and freedom from CD-TLR, although there were no statistically significant differences vs controls.
机译:目的:报告随机试验,将腿部紫杉醇洗脱球囊(PEB)+超级在中间体股动脉(SFA)病变患者中单独支撑到超级术。方法:多中心快速试验(控制--TriAls.com;标识符ISRCTN47846578)随机(1:1)160名患者(平均年龄67岁; 102名男性)与Rutherford 2-6类缺血与legflow peb +超级支架或超级治疗单独在中间体到长SFA病变(平均病变长度为15.8 +/- 7.4与15.8 +/- 7.6厘米)。疗效结果是主要的通畅,定义为从重新转移超声或血管造影的再狭窄的自由。结果:组之间包括闭塞百分比的基线特征在一起。在意向治疗分析中,PEB +超级组的1年估计的主要通畅性为68.3%(95%CI 56.7%至79.9%)与62.0%(95%CI 49.1%至74.9%)超级组(P = 0.900)。每协定分析显示,在对照组中,PEB +超级组的74.7%(95%CI 63.1%至86.3%)的初级通畅估计为62.0%(95%CI 49.1%至74.9%)(P. = 0.273)。 12个月(每种方案分析)的二级通用估计为89.0%(95%CI 80.6%至97.4%)与98.0%(95%CI 94.1%至100%; P = 0.484);从临床驱动的目标病变血运重建(CD-TLR)的自由估计分别为83.0%(95%CI 72.8%至93.2%)和77.8%(95%CI 66.6%至89.0%; p = 0.277)。结论:多中心快速随机对照试验的短期结果表明,腿部PEB对于治疗中间体至长SFA病变是安全可行的。在这项试验中,至少70%的患者遭受了闭塞。 PEB组具有较高的主要堤防和来自CD-TLR的自由率,尽管没有统计学上显着的差异VS控制。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号